Cancer

Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008

Published in OBGYN and Reproduction Week, November 3rd, 2008

ACCESS PHARMACEUTICALS, INC. (BULLETIN BOARD: ACCP) announced that three posters describing significant recent results of the company's proprietary polymer DACH platinum prodrug, ProLindac, in clinical and preclinical studies are being presented this week at a major international oncology conference held in Geneva, Switzerland.

The clinical poster highlights results from the multi-center Phase 2 recurrent ovarian cancer trial in France where the level of anti-cancer activity of ProLindac in a heavily-pretreated patient population compares favorably to previously published results of single agent oxaliplatin in patients that had less pretreatment. These promising...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of OBGYN and Reproduction Week

Source: OBGYN and Reproduction Week (2008-11-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry